TY - JOUR
T1 - Serum Proteomic Profiles Suggest Celecoxib-Modulated Targets and Response Predictors
AU - Xiao, Zhen
AU - Luke, Brian T.
AU - Izmirlian, Grant
AU - Umar, Asad
AU - Lynch, Patrick M.
AU - Phillips, Robin K.S.
AU - Patterson, Sherri
AU - Conrads, Thomas P.
AU - Veenstra, Timothy D.
AU - Greenwald, Peter
AU - Hawk, Ernest T.
AU - Ali, Iqbal U.
PY - 2004/4/15
Y1 - 2004/4/15
N2 - Cyclooxygenase-2 is a valid target for cancer prevention and treatment. This has been shown in preclinical and clinical cancer prevention studies by using a cyclooxygenase-2 inhibitor, celecoxib. When used in a randomized cancer prevention clinical trial on patients with the inherited autosomal dominant condition, familial adenomatous polyposis, celecoxib proved efficacious. However, a remarkable heterogeneity in patients' responses to the chemopreventive effects of celecoxib was observed. Proteomic profiling of sera from these patients identified several markers, the expression of which was specifically modulated after treatment with celecoxib. A decision tree algorithm identified classifiers for response to celecoxib with relatively high sensitivity but moderate to low specificity. In particular, a spectral feature at m/z 16,961.4 was identified as a strong discriminator between response and nonresponse to celecoxib at the highest dose.
AB - Cyclooxygenase-2 is a valid target for cancer prevention and treatment. This has been shown in preclinical and clinical cancer prevention studies by using a cyclooxygenase-2 inhibitor, celecoxib. When used in a randomized cancer prevention clinical trial on patients with the inherited autosomal dominant condition, familial adenomatous polyposis, celecoxib proved efficacious. However, a remarkable heterogeneity in patients' responses to the chemopreventive effects of celecoxib was observed. Proteomic profiling of sera from these patients identified several markers, the expression of which was specifically modulated after treatment with celecoxib. A decision tree algorithm identified classifiers for response to celecoxib with relatively high sensitivity but moderate to low specificity. In particular, a spectral feature at m/z 16,961.4 was identified as a strong discriminator between response and nonresponse to celecoxib at the highest dose.
UR - http://www.scopus.com/inward/record.url?scp=5444266793&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=5444266793&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-03-3754
DO - 10.1158/0008-5472.CAN-03-3754
M3 - Article
C2 - 15087410
AN - SCOPUS:5444266793
SN - 0008-5472
VL - 64
SP - 2904
EP - 2909
JO - Cancer Research
JF - Cancer Research
IS - 8
ER -